Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

REYVOW® (lasmiditan): Concomitant Use With CGRP Monoclonal Antibodies

Concomitant use of Reyvow (lasmiditan) with CGRP monoclonal antibodies has not been studied.

Concomitant Use With CGRP Monoclonal Antibodies

Lasmiditan has been studied in 2 phase 3 randomized, double-blind, placebo-controlled single attack studies in adult patients for the acute treatment of migraine: SAMURAI and SPARTAN.1,2

CGRP monoclonal antibodies are indicated for the preventive treatment of migraine in adults.3-6

During the lasmiditan phase 3 studies in adult patients for the acute treatment of migraine 

  • use of concomitant medication to reduce the frequency of migraine attacks was allowed in certain circumstances, however

  • CGRP monoclonal antibodies were investigational products not available for commercial use at the time of the studies.3

Concomitant use of lasmiditan with CGRP monoclonal antibodies has not been studied.

Enclosed Prescribing Information

REYVOW® (lasmiditan) tablets, for oral use, CV, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1. Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232. http://dx.doi.org/10.1212/WNL.0000000000006641

2. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-1904. http://dx.doi.org/10.1093/brain/awz134

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Aimovig [package insert]. Thousand Oaks, CA: Novartis; 2019.

5. Ajovy [package insert]. North Wales, PA: Teva; 2018.

6. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Glossary

CGRP = calcitonin gene-related peptide

Date of Last Review: August 27, 2018


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical